Zymeworks Takes Poison Pill to Block Hostile Bid
Related Posts
AbbVie’s $1.4B Alzheimer’s Bet: Game Changer or Risky Gamble?
Strategic Acquisition: AbbVie's $1.4 billion acquisition of Aliada Therapeutics signals a significant bet on Alzheimer's disease treatment, bolstering its pipeline with a Phase I anti-amyloid...
Luxury Merger Blocked: Tapestry-Capri Deal Faces Antitrust Setback
Antitrust Scrutiny: The blocked $8.5 billion Tapestry-Capri merger highlights increasing antitrust scrutiny in the luxury fashion industry, as regulators aim to protect consumer interests and...
Carlyle Retreats from Thyssenkrupp Defence Bid: Berlin’s Regulatory Uncertainty Impacts M&A
Regulatory Hurdles: Carlyle Group's withdrawal from bidding for Thyssenkrupp's defence unit highlights the significant regulatory challenges in Germany's defence industry M&A landscape. Strategic...
FTC Probes Boeing’s $4.7B Spirit Aero Buy: Antitrust Fears and Industry Impact
Strategic Acquisition: Boeing's $4.7 billion all-stock acquisition of Spirit AeroSystems aims to improve aircraft quality and safety by integrating Spirit's operations. Regulatory Scrutiny: The...